BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 27249730)

  • 1. Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer.
    Fujiwara K; McAlpine JN; Lheureux S; Matsumura N; Oza AM
    Am Soc Clin Oncol Educ Book; 2016; 35():e247-57. PubMed ID: 27249730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
    Ramalingam P
    Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.
    Kurman RJ; Shih IeM
    Hum Pathol; 2011 Jul; 42(7):918-31. PubMed ID: 21683865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extrauterine Pelvic Serous Carcinomas: Current Update on Pathology and Cross-sectional Imaging Findings.
    Katabathina VS; Amanullah FS; Menias CO; Chen MM; Valente PT; Chintapalli KN; Prasad SR
    Radiographics; 2016; 36(3):918-32. PubMed ID: 27163599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The molecular biology of epithelial ovarian cancer].
    Leary A; Pautier P; Tazi Y; Morice P; Duvillard P; Gouy S; Uzan C; Gauthier H; Balleyguier C; Lhommé C
    Bull Cancer; 2012 Dec; 99(12):1161-73. PubMed ID: 23238064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian serous carcinogenesis from tubal secretory cells.
    Zhang W; Wei L; Li L; Yang B; Kong B; Yao G; Zheng W
    Histol Histopathol; 2015 Nov; 30(11):1295-302. PubMed ID: 26174492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-grade serous carcinoma: molecular features and contemporary treatment strategies.
    Angarita AM; Cholakian D; Fader AN
    Expert Rev Anticancer Ther; 2015; 15(8):893-9. PubMed ID: 26040191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment.
    Lalwani N; Prasad SR; Vikram R; Shanbhogue AK; Huettner PC; Fasih N
    Radiographics; 2011; 31(3):625-46. PubMed ID: 21571648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular pathology of epithelial ovarian cancer.
    Christie M; Oehler MK
    J Br Menopause Soc; 2006 Jun; 12(2):57-63. PubMed ID: 16776856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-grade serous ovarian cancer: A review.
    Kaldawy A; Segev Y; Lavie O; Auslender R; Sopik V; Narod SA
    Gynecol Oncol; 2016 Nov; 143(2):433-438. PubMed ID: 27581327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Histological grading of epithelial ovarian cancer. Review and recommendation].
    Hauptmann S; du Bois A; Meinhold-Herlein I; Pfisterer J; Avril S
    Pathologe; 2014 Sep; 35(5):497-503. PubMed ID: 25069848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Fallopian Tubes in the Development of Ovarian Cancer.
    Corzo C; Iniesta MD; Patrono MG; Lu KH; Ramirez PT
    J Minim Invasive Gynecol; 2017 Feb; 24(2):230-234. PubMed ID: 28007588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.
    Ahmed N; Abubaker K; Findlay J; Quinn M
    J Cell Biochem; 2013 Jan; 114(1):21-34. PubMed ID: 22887554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endometriosis-associated Ovarian Cancers.
    Anglesio MS; Yong PJ
    Clin Obstet Gynecol; 2017 Dec; 60(4):711-727. PubMed ID: 28990985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.
    Kurman RJ; Shih IeM
    Am J Surg Pathol; 2010 Mar; 34(3):433-43. PubMed ID: 20154587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference.
    Jang JYA; Yanaihara N; Pujade-Lauraine E; Mikami Y; Oda K; Bookman M; Ledermann J; Shimada M; Kiyokawa T; Kim BG; Matsumura N; Kaku T; Kuroda T; Nagayoshi Y; Kawabata A; Iida Y; Kim JW; Quinn M; Okamoto A
    J Gynecol Oncol; 2017 Jul; 28(4):e54. PubMed ID: 28541641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathology of Ovarian Cancer: Recent Insights Unveiling Opportunities in Prevention.
    Kommoss F; Gilks CB
    Clin Obstet Gynecol; 2017 Dec; 60(4):686-696. PubMed ID: 28990983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma.
    Nik NN; Vang R; Shih IeM; Kurman RJ
    Annu Rev Pathol; 2014; 9():27-45. PubMed ID: 23937438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.